Cargando…

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China

PURPOSE: To evaluate the cost-utility of empagliflozin, in addition to best available standard care (BASC), for the treatment of adult patients with T2DM at high cardiovascular risk from the Chinese healthcare system perspective. METHODS: A Microsoft Excel-based patient-level simulation model, based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Men, Peng, Liu, Tianbi, Zhai, Suodi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431175/ https://www.ncbi.nlm.nih.gov/pubmed/32848438 http://dx.doi.org/10.2147/DMSO.S266901

Ejemplares similares

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
por: Ramos, Mafalda, et al.
Publicado: (2021)

Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost–Utility Analysis
por: Men, Peng, et al.
Publicado: (2020)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
por: Bernfort, Lars, et al.
Publicado: (2020)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis
por: Men, Peng, et al.
Publicado: (2018)

Cost-Effectiveness of Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Published Articles
por: Qiu, Tingting, et al.
Publicado: (2021)

Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes Mellitus
por: Albugami, Muneerah M., et al.
Publicado: (2020)

Options for empagliflozin in combination therapy in type 2 diabetes mellitus
por: Hershon, Kenneth S
Publicado: (2016)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
por: Munir, Kashif M, et al.
Publicado: (2016)

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2016)

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
por: Ehlers, Lars Holger, et al.
Publicado: (2021)

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
por: Anderson, John E., et al.
Publicado: (2016)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
por: Tang, Yi, et al.
Publicado: (2022)

Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis
por: Raju, Aditya, et al.
Publicado: (2021)

Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
por: Chauhan, Sukhjinder, et al.
Publicado: (2023)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
por: Levine, Matthew J.
Publicado: (2017)

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Kinduryte Schorling, Ona, et al.
Publicado: (2020)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
por: Al Jobori, Hussein, et al.
Publicado: (2018)

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
por: Mozawa, Kosuke, et al.
Publicado: (2021)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
por: Ramos, Mafalda, et al.
Publicado: (2019)

Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
por: Zhou, Pengxiang, et al.
Publicado: (2021)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial
por: Kansal, A., et al.
Publicado: (2019)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events
por: Towiargi, Ruba, et al.
Publicado: (2022)

Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes
por: Deng, Xinru, et al.
Publicado: (2022)

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
por: Neeland, Ian J, et al.
Publicado: (2016)

Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials
por: Zhang, Yun-Jing, et al.
Publicado: (2018)

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
por: Lunder, Mojca, et al.
Publicado: (2018)

Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus
por: Hsu, Jung-Chi, et al.
Publicado: (2019)

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial
por: Jürgens, Mikkel, et al.
Publicado: (2021)

Efficacy and Safety of Empagliflozin in the Management of Diabetes Mellitus in Heart Transplant Recipients
por: Cehic, Matthew G., et al.
Publicado: (2019)

Fournier’s Gangrene in an HIV-Positive Patient on Empagliflozin for the Treatment of Diabetes Mellitus
por: Khokhar, Farzam, et al.
Publicado: (2022)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6fgacuimmlcekibfo4249bgvkd